RSSCategory: Molecular Pathology

Fimmic Raises $6M Series A Round to Accelerate Scaling of its Deep Learning AI Cloud for Tissue Diagnostics

| December 11, 2017 | 0 Comments

Investments in the millions of dollars for Series A funding continue to interest investors for AI in digital pathology. The most recent news coming from Fimmic out of Finland and their $6M raise most recently bringing their total to $11M. Congratulations to Fimmic! Fimmic, a Finnish medtech company developing Deep Learning AI solutions for digital […]

Continue Reading

Digital Pathology Advancing Medicine to the Digital Age – Part of the 25th Annual Molecular Medicine Tri-Conference

| December 6, 2017 | 0 Comments

February 12-14, 2018   |   Moscone South Convention Center   |   San Francisco, CA Triconference.com/Digital-Pathology Bristol-Myers Squibb and Genentech to Present on Benefits of Multiplex Immunohistochemistry at CHI’s Digital Pathology Conference in San Francisco Multiplexes IHC and Image Analysis in Immuno-Oncology Drug Development and Companion Diagnostics Michael C. Montalto, Ph.D., Executive Director, Translational Medicine, Bristol-Myers Squibb Conventional immunohistochemistry, […]

Continue Reading

The Netherlands Cancer Institute Selects the HALO Image Analysis Platform to Expand its Immuno-oncology Research Capabilities

| October 29, 2017 | 0 Comments

Indica Labs, the leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce selection of the HALO image analysis platform by the Netherlands Cancer Institute (NKI) for in situ analysis of multiplexed biomarkers in tumor tissues. NKI will be using the HALO platform to analyze images captured from their Perkin […]

Continue Reading

MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services

| September 30, 2017 | 0 Comments

Portland OR – September 29, 2017 – MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug development programs, has announced a partnership agreement with Indica Labs, a leader in digital pathology imaging tools and services. The collaboration between the companies leverages MolecularMD’s diagnostic clinical testing solutions with Indica Labs’ digital biomarker analysis services to enable an efficient transition of pre-clinical […]

Continue Reading

Promega Intends to Seek FDA Approval for Microsatellite Instability Assay to Assist in Strategic Cancer Decisions

| July 9, 2017 | 0 Comments

Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega Research Use Only MSI Assay has been available and used in the market as part of Lab-Developed Tests since 2004 and is considered the […]

Continue Reading

Grail’s Billion Dollar Bet for the Perfect Cancer Test

| June 11, 2017 | 1 Comment

Thought this was worth sharing from MIT Technology Review. After attending ASCO last week what I thought might happen a year or two again actually has. Pathologists no longer have to worry about stepping out from behind the paraffin curtain as many of us were fond of saying. Tissue is not the issue anymore. At […]

Continue Reading

VisionGate Hires Dr. David Wilbur as Medical Director

| June 9, 2017 | 0 Comments

VisionGate, Inc. recently announced the appointment of Dr. David Wilbur as Medical Director of its Phoenix-based CLIA laboratory, VisionGate Biosignatures Laboratory (VBL). A world-renowned pathologist, Dr. Wilbur comes to VisionGate from Massachusetts General Hospital (MGH), where he has been a practicing pathologist since 2001. He headed the Cytopathology Unit until 2011, when he took over the […]

Continue Reading

FDA Approval of Immunotherapy For MSI-High or Mismatch Repair Deficient Tumors

| June 5, 2017 | 0 Comments

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment. KEYTRUDA has also been approved fro MSI-H or dMMR colorectal cancers that have progressed following treatment with conventional chemotherapies. The immunooncology/immunotherapy story is fascinating. […]

Continue Reading

Oncologists Say Genomic Testing Is Over Promoted Though It Is Likely To Be Useful Over The Next Decade

Fierce Healthcare (5/2, Sweeney) reports on a Medscape survey finding that among oncologists, about 70% “believe genetic testing is very important or extremely important to oncology, but 55% also say genomic testing is overpromoted.” One reason for that is that 89% believe “genomics will be useful in the next decade,” while just 64% “say it’s […]

Continue Reading

Trevor Heritage Joins Inspirata as Senior Vice President of Cancer Informatics

| February 21, 2017 | 0 Comments

Dr. Heritage is widely recognized for his work in the development of informatics systems for drug and performance chemical discovery, translational and personalized medicine, and pharmaceutical product development. San Francisco, CA, February 21, 2017  – Cancer diagnostics workflow solution provider Inspirata, Inc., is pleased to announce that Dr. Trevor Heritage has joined its executive team to […]

Continue Reading

‘Crosswalk’ Re-Launched to Make it Easier to Bridge the Gap Between Pathology, Precision Diagnosis and Precision Medicine

| February 20, 2017 | 1 Comment

Inspirata has just released new mobile and Web-based versions of “Crosswalk Insight: Oncology™,” a knowledge visualization platform that enables users to easily navigate through tumor images and the associated molecular pathways, targeted therapies and clinical trials. San Francisco, CA, February 20, 2017 – Cancer diagnostics and pathology workflow solution provider Inspirata®, Inc. announced today the re-launch […]

Continue Reading

XIFIN Executives to Present Sessions on Collaborative Diagnostic Workflows and Novel Diagnostic Technologies at 24th International Molecular Medicine Tri-Conference

| February 17, 2017 | 0 Comments

XIFIN Inc., the healthcare information technology company revolutionizing the business of healthcare diagnostics, will co-present a session with the University of Chicago on collaborative diagnostic workflows at the Cambridge Healthtech Institute’s Fifth Annual Digital Pathology conference, a track at the 24th International Molecular Medicine Tri-Conference being held February 20-22 at the Moscone Convention Center in San Francisco. David […]

Continue Reading

Will Not Using Image Analysis in Pathology be Perceived as Irresponsible? 

| February 1, 2017 | 0 Comments

Originally published by Simon Häger, Product Manager Sectra Digital Pathology Solution at Sectra.com.  It is hard to argue with any of the points raised here by Simon. No doubt image analysis will enable what we do to do it better. More quantitative analysis. Better, faster, cheaper, more accurate. Image analysis and tele-consultation have been and will […]

Continue Reading

Register Now to Attend Presentations from Inspirata at Molecular Med Tri-Con 2017

| January 26, 2017 | 0 Comments

Register now for Molecular Med Tri-Con 2017. Inspirata will provide the keys to unlock Precision Medicine through Digital Pathology at the Molecular Medicine Tri-Conference. Attend their presentations from Dr. Mark Boguski and Dr. Mark Lloyd. Use code 1737INP for discounted registration.

Continue Reading